Jiang Tian

Title: Innovations in Cancer Treatment by Inventor Jiang Tian

Introduction

Jiang Tian is a notable inventor based in Perrysburg, OH (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. With a total of 3 patents, his work focuses on the modulation of Src signaling pathways, which play a crucial role in cancer progression.

Latest Patents

Jiang Tian's latest patents include groundbreaking methods for treating cancer using Src-modulating peptides. One of his patents discloses a method for regulating Src and its downstream signaling pathway, which involves the binding between Src and Na+/K+-ATPase. This Na+/K+-ATPase/Src complex serves as a functional receptor for cardiotonic steroids such as ouabain. The patent also details Src inhibitors or activators that interfere with the interaction between Na+/K+-ATPase and Src, acting through a mechanism distinct from ATP analogues and being specific to the Na+/K+-ATPase pathway. Another patent highlights the use of Na+/K+-ATPase-specific peptide inhibitors and activators of Src and Src family kinases, further emphasizing the potential of these peptides in cancer treatment.

Career Highlights

Jiang Tian is affiliated with the University of Toledo, where he conducts his research and develops his innovative treatments. His work has garnered attention for its potential to revolutionize cancer therapy by targeting specific pathways involved in tumor growth and progression.

Collaborations

Some of Jiang Tian's notable coworkers include Joseph I Shapiro and Zi-Jian Xie, who contribute to the collaborative efforts in advancing cancer treatment research.

Conclusion

Jiang Tian's innovative approaches to cancer treatment through Src-modulating peptides represent a significant advancement in the field. His patents reflect a commitment to improving therapeutic options for cancer patients, showcasing the importance of targeted treatment strategies.